Neurocrine Biosciences Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio40.4951.8474.3290.1821.99
Forward P/E18.1521.3422.5324.5522.30
P/S Ratio5.876.867.717.138.56
P/B Ratio5.345.806.725.887.95
Price/Tangible Book5.425.916.895.887.95
Price/FCF24.8035.8035.5634.6641.15
Price/OCF23.2133.2033.8331.5039.19
PEG Ratio0.310.650.660.370.37
Enterprise Value Ratios
EV/Revenue5.476.427.376.858.15
EV/EBITDA21.1129.1441.4435.5125.37
EV/EBIT22.0930.7144.0437.3826.04
EV/FCF23.1133.5333.9633.3239.19
Profitability & Returns
Return on Equity (ROE)0.14%0.13%0.10%0.07%0.46%
Return on Assets (ROA)0.10%0.09%0.07%0.07%0.13%
Return on Invested Capital (ROIC)0.23%0.23%0.17%0.20%0.55%
Return on Capital Employed (ROCE)0.18%0.15%0.14%0.11%0.21%
Leverage & Solvency Ratios
Debt/Equity0.190.190.150.320.37
Debt/EBITDA0.760.990.941.881.19
Debt/FCF0.891.190.811.891.90
Liquidity Ratios
Current Ratio3.402.452.703.965.45
Quick Ratio3.062.252.493.655.14
Efficiency Ratios
Asset Turnover0.680.670.670.590.69
Inventory Turnover15.9916.4814.8511.7112.59
Yield & Distribution Ratios
Earnings Yield0.02%0.02%0.01%0.01%0.05%
FCF Yield0.04%0.03%0.03%0.03%0.02%
Buyback Yield-0.03%-0.02%-0.01%0.00%-0.02%